Table 1. Demographic details of treated and control patients.

DAS, disease activity score; RF, rheumatoid factor; MTX, methotrexate; SSZ, sulfasalazine; HCQ, hydroxychloroquine; LEF, leflunomide; TNFi, tumor necrosis factor inhibitor; N/A, not applicable.

Rheumavax Low
dose (n = 9)
Rheumavax High
dose (n = 9)
Control
Group 1 (n = 11)
Control
Group 2 (n = 5)
Age, mean (SD)56.8 (9)55.1 (10.1)57.6 (9.8)49.8 (10.8)
Females, n (%)5 (55)8 (89)6 (54)4 (88)
Disease duration (years),
median (IQR)
3 (1.5–4)2 (1–4)1 (1–2)2 (1–11)
Baseline DAS,
median (IQR)
2.43 (1.54–3.81)2.2 (1.56–3.3)2.81 (2.1–3.63)3.29 (2.75–3.83)
RF+, n (%)7 (78)9 (100)10 (91)4 (88)
Anti-CCP+, n (%)9 (100)9 (100)11 (100)5 (100)
HLA-DR SE+, n (%)9 (100)9 (100)11 (100)5 (100)
Other treatment, n (%)
  MTX7 (78)9 (100)7 (64)5 (100)
  SSZ2 (22)6 (67)5 (45)5 (100)
  HCQ5 (56)6 (67)8 (73)4 (88)
  LEF0 (0)0 (0)2 (18)1 (20)
TNFi2 (22)0 (0)0 (0)0 (0)
Rheumavax
  Dose/kg (range)7.2 × 103 to 1.7 × 1042.7 × 104 to 6.2 × 104N/AN/A
  Adverse events, n (%)4 (44)5 (56)N/AN/A